The roles of cocoa powder in the treatment of steroid induced hypertension in pediatric patients with atutoimmune diseases

The roles of cocoa powder in the treatment of steroid-induced hypertension in pediatric patients with autoimmune diseases

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200804007

Enrollment

Registered

2020-08-04

Start date

2020-08-04

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric autoimmune diseases receiving steroid treatment autoimmune diseases steroid induced hypertension

Interventions

Cocoa powder

Experimental Dietary Supplement

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Pediatric autoimmune diseases requiring steroid with hypertension

Exclusion criteria

Exclusion criteria: History of glomerulonephritis Allergic to cocoa powder Severe hypertension

Design outcomes

Primary

Measure	Time frame
Outcomes of blood pressure reduction of cocoa powder 30 days Blood pressure reduction,	—

Secondary

Measure	Time frame
Effect of cocoa powder on reduction of inflammation in autoimmune diseases 30 days ESR	—

Countries

Thailand

Contacts

Public ContactKwanchai Pirojsakul

Ramathibodi Hospital

puggyth@gmail.com022011497

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026